Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers

References

• Andresson T, Hassan-Alin M, Hasselgren G, et al. (2001). Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:411–26
   PubMed Web of Science ®Google Scholar
• Boparai V, Rajagopalan J, Triadafilopoulos G. (2008). Guide to the use of proton pump inhibitors in adult patients. Drugs 68:925–47
   PubMed Web of Science ®Google Scholar
• Commandeur JN, Stijntjes GJ, Vermeulen NP. (1995). Enzymes and transport system involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Pharmacol Rev 47:271–330
   PubMed Web of Science ®Google Scholar
• Delhotal-Landes B, Flouvat B, Duchier J, et al. (1993). Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367–71
   PubMed Web of Science ®Google Scholar
• Echizen H. (2016). The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 55:409–18
   PubMed Web of Science ®Google Scholar
• EMA (2012). Guideline on the investigation of drug interactions. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 29 Aug 2017]
   Google Scholar
• FDA (2016). Safety testing of drug metabolites guidance for industry. US Food and Drug Administration. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079266.pdf [last accessed 29 Aug 2017]
   Google Scholar
• Furuta T, Ohashi K, Kobayashi K, et al. (1999). Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66:265–74
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Watanabe F, et al. (2002). Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–60
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. (2005). Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153–67
   PubMedGoogle Scholar
• Grabowski B, Lee RD. (2012). Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig 32:319–32
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Andersson T, Niazi M, et al. (2006). Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther 44:119–27
   PubMed Web of Science ®Google Scholar
• ICH (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. International Council for Harmonization of Technical Requirements for Pharmaceuticals for human use. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf [last accessed 29 Aug 2017]
   Google Scholar
• Ichikawa H, Sugimoto M, Sugimoto K, et al. (2016). Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 31:716–26
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. (1999). Review article: cytochrome P450 and the metabolism of proton pump inhibitors–emphasis on rabeprazole. Aliment Pharmacol Ther 13 (Suppl 3):27–36
   PubMed Web of Science ®Google Scholar
• Jenkins H, Jenkins R, Patat A. (2017). Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Clinical Drug Investigation 37:311–16
   PubMed Web of Science ®Google Scholar
• Kodama K, Fujisaki H, Kubota A, et al. (2010). E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion. J Pharmacol Exp Ther 334:395–401
   PubMed Web of Science ®Google Scholar
• Klotz U. (2000). Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 38:243–70
   PubMed Web of Science ®Google Scholar
• Lassen AT. (2007). Acid-related disorders and use of antisecretory medication. Dan Med Bull 54:18–30
   PubMed Web of Science ®Google Scholar
• Naesdal J, Andersson T, Bodemar G, et al. (1986). Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 40:344–51
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. (2006). Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23 (Suppl 2):2–8
   PubMed Web of Science ®Google Scholar
• Setoyama T, Drijfhout WJ, van de Merbel NC, et al. (2006). Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Int J Clin Pharmacol Ther 44:557–65
   PubMed Web of Science ®Google Scholar
• Shamburek RD, Schubert ML. (1992). Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K+-ATPase inhibitors . Gastroenterol Clin North Am 21:527–50
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. (2013). Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 19:25–35
   PubMed Web of Science ®Google Scholar
• Vandenbranden M, Ring BJ, Binkley SN, Wrighton SA. (1996). Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81–91
   PubMedGoogle Scholar
• Yasui-Furukori N, Saito M, Uno T, et al. (2004a). Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44:1223–9
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Takahata T, Nakagami T, et al. (2004b). Different inhibitory effects of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 54:487–94
   Web of Science ®Google Scholar